Evidence map›Paper›PMID 25848467›Full record

ReviewWorld journal of hepatology2015

Staging systems for hepatocellular carcinoma: Current status and future perspectives.

Akiyoshi Kinoshita, Hiroshi Onoda, Nao Fushiya, Kazuhiko Koike, Hirokazu Nishino, Hisao Tajiri

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Liquid Liver Biopsy for Disease Diagnosis and Prognosis.Journal of clinical and translational hepatology · 2023
    Review
  19. Review
  20. Review

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Akiyoshi KinoshitaAkiyoshi Kinoshita, Hiroshi Onoda, Nao Fushiya, Kazuhiko Koike, Hirokazu Nishino, Division of Gastroenterology and Hepatology, the Jikei University Daisan Hospital, Tokyo 201-8601, Japan.
Hiroshi OnodaAkiyoshi Kinoshita, Hiroshi Onoda, Nao Fushiya, Kazuhiko Koike, Hirokazu Nishino, Division of Gastroenterology and Hepatology, the Jikei University Daisan Hospital, Tokyo 201-8601, Japan.
Nao FushiyaAkiyoshi Kinoshita, Hiroshi Onoda, Nao Fushiya, Kazuhiko Koike, Hirokazu Nishino, Division of Gastroenterology and Hepatology, the Jikei University Daisan Hospital, Tokyo 201-8601, Japan.
Kazuhiko KoikeAkiyoshi Kinoshita, Hiroshi Onoda, Nao Fushiya, Kazuhiko Koike, Hirokazu Nishino, Division of Gastroenterology and Hepatology, the Jikei University Daisan Hospital, Tokyo 201-8601, Japan.
Hirokazu NishinoAkiyoshi Kinoshita, Hiroshi Onoda, Nao Fushiya, Kazuhiko Koike, Hirokazu Nishino, Division of Gastroenterology and Hepatology, the Jikei University Daisan Hospital, Tokyo 201-8601, Japan.
Hisao TajiriAkiyoshi Kinoshita, Hiroshi Onoda, Nao Fushiya, Kazuhiko Koike, Hirokazu Nishino, Division of Gastroenterology and Hepatology, the Jikei University Daisan Hospital, Tokyo 201-8601, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a major health concern worldwide and the third cause of cancer-related death. Despite advances in treatment as well as careful surveillance programs, the mortality rates in most countries are very high. In contrast to other cancers, the prognosis and treatment of HCC depend on the tumor burden in addition to patient's underlying liver disease and liver functional reserve. Moreover, there is considerable geographic and institutional variation in both risk factors attributable to the underlying liver diseases and the management of HCC. Therefore, although many staging and/or scoring systems have been proposed, there is currently no globally accepted system for HCC due to the extreme heterogeneity of the disease. The aim of this review is to focus on currently available staging systems as well as those newly reported in the literatures since 2012. Moreover, we describe problems with currently available staging systems and attempts to modify and/or add variables to existing staging systems.

Indexed as

Hepatocellular carcinomaPrognosisScoring systemStaging system

Identifiers

PMID25848467
PMCPMC4381166

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.